Prognostic relevance of molecular markers of oral cancer - A review

International Journal of Oral and Maxillofacial Surgery

Volumn 32, Issue 3, 2003, Pages 233-245

  Schliephake, H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Adhesion molecules; Angiogenesis; Apoptosis; Cell cycle; Oral squamous cell carcinoma; Proliferation; Tumour markers

Indexed keywords

CADHERIN; CATENIN; CATHEPSIN; CELL ADHESION MOLECULE; CELL NUCLEUS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DESMOPLAKIN; FAS ANTIGEN; FAS LIGAND; HEAT SHOCK PROTEIN 27; INTEGRIN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; NITRIC OXIDE SYNTHASE; PLAKOGLOBIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; RETINOBLASTOMA PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR ETS 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CELL PROLIFERATION; DIAGNOSTIC VALUE; EXTRACELLULAR MATRIX; GROWTH ACCELERATION; HUMAN; IMMUNE RESPONSE; MEDICAL LITERATURE; METASTASIS POTENTIAL; MOUTH CANCER; PROGNOSIS; PROTEIN DEGRADATION; QUANTITATIVE ASSAY; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

EID: 0037864294     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1054/ijom.2002.0383     Document Type: Review

References (169)

1. AGARWAL S, MATHUR M, SHUKLA NK, RALHAN R. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncol 1998: 34: 353-360.
2. ALCALDE RE, TERAKADO N, OTSUI K, MATSUMZRA T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral sqamous cell carcinoma. Oncology 1997: 54: 324-328.
3. ARENAS-HUERTERO FJ, HERRERA-GOEPFERT R, DELGAD CHEVEZ R, ZINSER-SIERRA JW, DE LA GARZA-SALAZAR JG, HERRERA-GOMEZ A, PEREZ-CARDENAS E. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: Correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J Exp Clin Cancer Res 1999: 18: 279-284.
4. ARTESE L, RUBINI C, FERRERO G, FIORONI M, SANTINELLI A, PIATELLI A. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 2001: 21: 689-695.
5. BAGUTTI C, SPEIGHT PM, WATT FM. Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol 1998: 186: 8-16.
6. BAIR EL, MASSEY CP, TRAN NL, BORCHERS AH, HEIMARK RL, CRESS AE, BOWDEN GT. Integrin- and catherin-mediated induction of the matrix metalloprotease matrilysin in cocultures of malignant oral squamous cell carcinoma cells and dermal fibroblasts. Exp Cell Res 2001: 270: 259-267.
7. BANKFALVI A, PIFKO J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med 2000: 29: 291-298.
8. BENTZ BG, CHANDRA R, HAINES GK 3RD, ROBINSON AM, SHAH P, RADOSEVICH JA. Nitric oxide and apoptosis during human head and neck squamous cell carcinoma development, Am J Otolaryngol 2002: 23: 4-11.
9. BHALANG K, KAFRAWY AH, MILES DA. Immunohistochemical study of the re-expression of human chorionic gonadotropin-beta in oral squamous cell carcinoma. Cancer 1999: 85: 757-762.
10. BILGEN C, SARIOGLU S, CERYAN K. Evaluation of the primary tumour and the metastatic lymph node with or without extracapsular spread by means of agyrophilic nucleolar regions (AgNOR). Rev Laryngol Otol Rhinol 2000: 121: 155-159.
11. BIRCHALL MA, SCHOCK E, HARMON BV, GOBE G. Apoptosis, mitosis, PCNA and bcl-2 in normal, leukoplakic and malignant epithelia of the human cavity: prospective, in vivo study.
12. BIRKEDAL-HANSEN B, PAVELIC ZP, GLUCKMANN JL, STAMBROOK P, LI YQ, STETLER-STEVENSON WG. MMP and TIMP gene expression in head and neck sqamous cell carcinomas and adjacent tissues. Oral Dis 2000: 6: 376-382.
13. BRADLEY G, IRISH J, MACMILLAN C, MANCER K, WITTERICK I, HARTWICK W, GULLANE P, KAMEL-REID S, BENCHIMOL S. Abnormalities of the ARF-p35 pathway in oral squamous cell carcinoma. Oncogene 2001: 20: 654-658.
14. BRENNAN PA, PALACIOS-CALLENDER M, ZAKI GA, SPEDDING AV, LANGDON JD. Type II nitric oxide synthase (NOS2) expression correlates with lymph node status in oral squamous cell carcinoma. J Oral Pathol Med 2001: 30: 129-134.
15. BRENNAN PA, PALACIOS-CALLENDER M, UMAR T, HUGHES D, SPEDDING AV, ZAKI GA, LANGDON JD. Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2000: 38: 627-632.
16. BRENNAN PA, PALACIOS-CALLENDER M, ZAKI GA, SPEDDING AV, LANGDON JD. Does type II nitric oxide synthase expression correlate with cellular proliferation in oral squamous cell carcinoma and dysplasia? Head Neck 2001: 23: 217-222.
17. BRENNAN PA, PALACIOS-CALLENDER M, UMAR T, TANT S, LANGDON JD. Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2002: 31: 200-205.
18. BRENNAN PA, UMAR T, SMITH GI, LO CH, TANT S. Expression of nitric oxide synthase-2 in cutaneous squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 2002: 40: 191-194.
19. BRYNE M. Is the invasive front of an oral carcinoma the most important area for prognostication. Oral Diseases 1998: 4: 70-77.
20. BRYSK MM, LEI G, ADLER-STORTHZ K, CHEN Z, BRYSK H, TYRING SK, ARANY I. Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Left 1999: 137: 117-120.
21. CARLILE J, HARADA K, BAILLIE R, MACLUSKEY M, CHISHOLM DM, OGDEN GR, SCHOR SL, SCHOR AM. Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. J Oral Pathol Med 2001: 30: 449-457.
22. CHANG LY, LIN SC, CHANG CS, WONG YK, Hu YCV, CHANG KW. Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis. J Oral Pathol Med 1999: 28: 389-396.
23. CHEN Q, SAMARANAYAKE LP, ZHEN X, LUO G, NIE M, LI B. Up-regulation of Fas ligand and down regulation of Fas expression in oral carcinogenesis. Oral Oncol 1999: 35: 548-553.
24. CHEN Q, ZHOU W, SAMARANAYAKE LP, ZHOU M, LI B. Correlation between the expression of cyclin A protein and p53 activity in oral squamous cell carcinomas. Cytobios 2001: 106: 87-99.
25. CHIANG CP, HUANG JS, WANG JT, LIU BY, KUO YS, HAHN LJ, KUO MY. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Pathol Med 1999: 72-76.
26. COUTURE C, RAYBAUD-DIOGENE H, TETU B, BAIRATI I, MURRY D, ALLARD J, FORTIN A. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002: 94: 713-722.
27. CRUZ IB, SNIJDERS PCV, MEIJER CJ, BRAAKHUIS BJ, SNOW GB, WALBOOMERS JM, VAN DER WAAL I. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998: 184: 360-368.
28. DANIELE E, RODOLICO V, LEONARDI V, TRALONGO V. Prognosis in lower lip squamous cell carcinoma: assessment of tumor factors. Pathol Res Pract 1998: 194: 319-324.
29. DENG Y, YUAN X, CHEN Z. Immunobiological significance of S-100 protein positive dendritic cells in patients wih oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi 1997: 32: 174-176.
30. DEPONDT J, SHABANA AH, FLORESCU-ZORILA S, GEHANNO P, FOREST N. Down-regulaton of desmosomal molecules in oral and pharyngeal squamous cell carcinomas as a marker for tumour growth and distant metastasis. Eur J Oral Sci 1999: 107: 183-193.
31. DEPONDT J, SHABANA AH, SAWAF H, GEHANNO P, FOREST N. Cytokeratin alterations as diagnostic and prognostic markers of oral and pharyngeal carcinomas. A prospective study. Eur J Oral Sci 1999: 107: 442-454.
32. DE ROSA I, STAIBANO S, LO MUZIO L, DELFINO M, LUCARIELLO A, COPPOLA A, DE ROSA G, SCULLY C. Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53 and c-myc in differentiation and prognosis. J Oral Pathol 1999: 28: 252-258.
33. EI-NAGGAR AK, LAI S, CLAYMANN GL, ZHOU JH, TUCKER SA, MYERS J, LUNA MA, BENEDICT WF. Expression of p16, Rb and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 1999: 30: 1001-1003.
34. FABBROCINI G, RUSSO N, PAGLIU MC, DELFINO M, STAIBANO, MOLEA G, MANCINI A, VIRGILI A, VALENTE MG, BRATINA G, GALBIATI S, MARZADURI A, ORLANDI K, BOTTONI U, CALVIERI S, DI LANDRO A, CAINELLI T, DELINO S, DE ROSA G. p53, cyclin-D1, PCNA, AgNOR expression in squamous cell cancer of the lip. A multicenter study. Photodermatol Photoimmunol Photomed 2000: 16: 172-177.
35. FONSECA LM, DO CORMA MA. AgNORs in hyperplasia, papilloma and oral squamous cell carcinoma. Braz Dent J 2000: 11: 105-110.
36. FORTIN A, RIBAUD-DIOGENE H, TETU B, HUOT J, BLONDEAU L, LANDRY J. Markers of neck failure in oral cavity and oropharyngeal carcinomas treated with radiotherapy. Head Neck 2001: 23: 87-93.
37. FUJIEDA S, INUZUKA M, TANAKA N, SUNAGA H, FAN GK, ITO T, SUGIMOTO C, TUZUKI H, SAITO H. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999: 84: 315-320.
38. FUJIEDA S, SUNAGA H, TSUZUKI H, FAN GK, ITO T, SUGIMOTO C, SAITO H. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer Left 2000: 161: 73-81.
39. GANDOUR-EDWARDS R, TROCK BJ, GUMERLOCK P, DONALD PJ. Heat shock protein and p53 expression in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1998: 118: 610-615.
40. GANDOUR-EDWARDS R, TROCK B, DONALD PJ. Predictive value of cathepsin-D for cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 1999: 21: 718-722.
41. GIROD SC, PFEIFFER P, RIES J, PAPE HD. Proliferative activity and loss of function of tumour suppressor gene as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma . Br J Oral Maxillofac Surg 1998: 36: 252-260.
42. GLEICH LL, ZIMMERMAN N, WANG YO, GLUCKMAN JL. Angiogenic inhibition for the treatment of head and neck cancer. Anticancer Res 1998: 18: 2607-2609.
43. GLEICH LL, BIDDINGER PW, DUPERIER FD, GLUCKMAN JL. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: a clinical-pathologic correlation. Head Neck 1997: 19: 276-280.
44. GOLDMAN SA, BAKER E, WEYANT RJ, CLARKE MR, MYERS JN, LOTZE MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998: 124: 641-646.
45. GONZALES-MOLES MA, RUIZ-AVILLA I, RODRIGUEZ-ARCHILLA A, MARTINEZ-LARA I. Suprabasal expression of Ki-67 antigen as a marker for the presence and severity of oral dysplasia. Head Neck 2000: 22: 658-661.
46. GONZALES-MOLES MA, CABALLERO R, RODRIGUEZ-ARCHILLA A, RUIZ-AVILLA I, BRAVO I. Prognosis value of the expression of Ki-67 for squamous cell carcinoma of the oral cavity. Acta Stomatol Belg 1997: 93: 159-165.
47. GSTAIGER M, JORDAN R, LIM M, CATZAVELOS C, MESTAN J, SLINGERLAND J, KREK W. Skp2 is oncogenic and over-expressed in human cancers. Proc Natl Acad Sci USA 2001: 98: 5043-5048.
48. GUAN WQ, YU SF, GAO Y. Alteration of Fas/FasL expression of oral squamous cell carcinoma cell line Tca83 induced by retinoid acid. Chin J Dent Res 2000: 3: 35-39.
49. HAGUE A, PACKHAM G, HUNTLEY S, SHEFFORD K, EVESON JW. Deregulated Bag-1 protein expression in human oral squamous cell carcinomas and lymph node metastases. J Pathol 2002: 197: 60-71.
50. HIDA K, SHINDOH M, YOSHIDA K, KUDOH A, FURAOKA K, KOHGO T, FUJINAGA K, TOTSUKA Y. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol 1997: 33: 426-430.
51. HONG SD, HONG SP, LEE JI, LIM CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metabolic potential. Oral Oncol 2000: 36: 207-213.
52. IBRAHIM SO, VASSTRAND EN, LIAVAAG PG, JOHANNESSEN AC, LILLEHAUG JR. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997: 17: 4539-4546.
53. IKEBE T, SHINOHARA M, TAKEUCHI H, BEPPU M, KURAHARA S, NAKAMURA S, SHIRASUNA K. Gelatinolytic activity of matrix metalloproteinases in tumor tissues correlates with the invasivenees of oral cancer. Clin Exp Metastasis 1999: 17: 315-323.
54. ITO R, YASUI W, OGAWA T, TOYOSAWA S, TAHARA E, IJUHIN N. Reduced expression of cyclin-dependent kinase inhibitor p27(Kip1) I oral malignant tumors. Pathobiology 1999: 67: 169-173.
55. KANG MK, PARK NH. Conversion of normal to malignant phenotype: telomere shortening, telomerase activation and genomic instability during immortalization of human oral keratinocytes. Crit Rev Oral Biol Med 2001: 12: 38-54.
56. KAPLAN I, VERED M, MOSKONA D, BUCHNER A, DAYAN D. An immunohistochemical study of p53 and PCNA in inflammatory papillary hyperplasia of the palate: a dilemma of interpretation. Oral Dis 1998: 4: 194-199.
57. KAPRANOS N, STATHOPOULOS GP, MANOLOPOULOS L, KOKKA E, PAPADIMITRIOU C, BIBAS A, YIOTAKIS J, ADAMOPOULOS G. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 2001: 21: 521-528.
58. KAUR J, KAUR J, RALHAN R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int J Cancer 2000: 85: 1-5.
59. KAWAMATA H, NAKASHIRO K, UCHIDA D, HARADA K, YOSHIDA H, SATO M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997: 70: 120-127.
60. KAWAMATA H, UCHIDA D, HAMANO H, KIMURA-YANAGAWA T, NAKASHIRO KI, HINO S, OMOTEHARA F, YOSHIDA H, SATO M. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymphnodes metastasis. Int J Oncol 1998: 13: 699-704.
61. KOELBL O, ROSENWALD A, HABERL M, MULLER J, REUTHER J, FLENTJE M. p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? An immunohistochemical and clinicopathologic study. Int J Radiat Oncol Biol Phys 2001: 49: 147-154.
62. KOONTONGKAEW S, CHAREONKITKAJORN L, CHANVITAN A, LEELAKRIANGSAK M, AMOMPHIMOLTAM P. Alterations of p53, pRb, Cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 2000: 36: 334-339.
63. KOWALSKI LP, MEDINA JE. Nodal metastases: predictive factors. Otolaryngol Clin North Am 1998: 31: 621-637.
64. KUDO Y, TAKATA T, OGAWA I, ZHAO M, SATO S, TAKEHOSHI T, MIYAUCHI M, NIKAI H. Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett 2000: 151: 217-222.
65. KUDO Y, TAKATA T, OGAWA I, KANEDA T, SATO S, TAKEKOSHI T, ZHAO M, MIYAUCHI M, NIKAI H. p27kip1 accumulate by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000: 6: 916-923.
66. KUDO Y, KITAJIMA S, SATO S, MIYAUCHI M, OGWAWA I, TAKATA T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001: 61: 7044-7047.
67. KUO MY, LIN CY, HAHN LJ, CHENG SJ, CHIANG CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 1999: 28: 165-169.
68. KUO MY, HSU HY, KOK SH, KUO RC, YANG H, HAHN LJ, CHIANG CP. Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 2002: 38: 172-178.
69. KURAHARA S, SHINOHARA M, IKEBE T, NAKAMURA S, BEPPU M, HIRAKI A, TAKEUCHI H, SHIRASUNA K. Expression of MMPs, MTMMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis. Head Neck 1999: 21: 627-638.
70. KUSHNER J, BRADLEY G, JORDAN RC. Patterns of p53 and Ki-67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol 1997: 183: 418-423.
71. KUSHNER J, BRADLEY G, YOUNG B, JORDAN RC. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med 1999: 28: 77-81.
72. LAM KY, NG IO, YUEN AP, KWONG DL, WEI W. Cyclin D1 expression in oral squamous cell carcinomas clinico-pathological relevance and correlation with p53 expression. J Oral Pathol Med 2000: 29: 167-172.
73. LEONARDI R, PANNONE G, MAGRO G, KUDO Y, TAKATA T, LO MUZIO L. Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and squamous cell carcinoma. Oncol Rep 2002: 9: 261-266.
74. LIAO J, MITSAUYASU T, YAMANE K, OHISHI M. Telomerase activity in oral and maxillofacial tumors. Oral Oncol 2000: 36: 347-352.
75. LO MUZIO L, PANNONE G, STAIBANO S, MIGNOGNA MD, SERPICO R, FANALI S, DE ROSA G, PIATTELLI A, MARIGGIO MA. p120(cat) Delocalization in cell lines of oral cancer. Oral Oncol 2002: 38: 64-72.
76. LO MUZIO L, STAIBANO S, PANNONE G, GRIECO M, MIGNOGNA MD, CERRATO A, TESTA NF, DE ROSA G. Beta- and gamma-catenin expression in oral squamous cell carcinomas. Anticancer Res 1999: 19: 3817-3826.
77. LOPES MA, NIKITAKIS NG, REYNOLDS MA, ORD RA, SAUK J JR. Biomarkers predictive of lymph node metastases in oral squamous cell carcinoma. J Oral Maxillofac Surg 2002: 60: 142-147.
78. LORO LL, VINTERMYR OK, JOHANNESSEN AC, LIAVAAG PG, JONSSON R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999: 28: 82-87.
79. LORO LL, VINTERMYR OK, LIAVAAG PG, JONSSON R, JOHANNESSEN AC. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expression ratio and increased apoptosis. Human Pathol 1999: 30: 1097-1105.
80. MASUDA M, SUZUI M, YASUMATU R, NAKASHIMA T, KURATOMI Y, AZUMA K, TOMITA K, KOMIYAMA S, WEINSTEIN IB. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002: 62: 3351-3355.
81. MATSUMOTO M, KOMJYAMA K, OKAUE M, SHIMOYAMA Y, IWAKAMI K, NAMAKI S, TANAKA H, MORO I, SATO H. Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67. J Oral Sci 1999: 41: 53-56.
82. MIGALDI M, CRISCULO M, ZUNARELLI E, LO BIAMCO L, MARTINELLI AM, BARBOLINI G. p120 and AgNOR nucleolar protein expression: a comparison with nuclear proliferating markers in oral pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998: 85: 189-196.
83. MISHIMA K, YAMADA E, MASUI K, SHIMOJAWARA T, TAKAYAMA K, SUGIMURA M, ICHIJIMA K. Over-expression of ERK/MAP kinases in oral squamous cell carcinoma. Modern Pathol 1998: 11: 986-889.
84. MORIYAMA M, KUMAGAI S, KAWASHIRI S, KOJIMA K, KAKAIHARA K, YAMAMOTO E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997: 33: 369-374.
85. MURAKI Y, YOSHIOKA C, TATEISHI A, FUKUDA J, HANEJI T, KOBAYASHI N. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1999: 37: 37-40.
86. MURAKI Y, TATEISHI A, SETA C, FUKUDA J, HANEJI T, OYA R, IKEMURA K, KOBAYASHI N. Fas antigen expression and outcome of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2000: 29: 360-365.
87. MURTI PR, WARNAKULASYRIYA KA, JOHNSON NW, BHONSLE RB, GUPTA PC, DAFTARY DK, MEHTA FS. p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 1998: 27: 191-196.
88. MYOUNG H, HONG SD, KIM YY, HONG SP, KIM MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001: 26; 163: 191-200.
89. NAKAHARA Y, SHINTANI S, MIHARA M, KIYOTA A, UEYAMA Y, MATSUMARA T. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 2000: 160: 3-8.
90. NG IO, LAM YK, REGEZI JA. Expression of p21/waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 and cellular proliferation index. Oral Oncol 1999: 35: 63-69.
91. NIWA S, UENO S, SHIRASU R. Alteration of pRb expression in the development of rat tongue carcinoma induced by 4-nitroquinoline 1-oxide. Oral Oncol 2001: 37: 579-585.
92. NOR JE, CHRISTENSEN J, LIU J, PETERS M, MOONEY DJ, STRIETER RM, POLVERINI PJ. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001: 61: 2183-2188.
93. OPITZ OG, SULIMAN Y, HAHN WC, HARADA H, BLUM HE, RUSTGI AK. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001: 108: 665-667.
94. PANDE P, MATHUR M, SHUKLA NK, RALHAN R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 1998: 34: 396-403.
95. PANDE P, MATHUR M, SHUKLA NK, RALHAN R. Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinoma. J Pathol 1999: 189: 40-45.
96. PIATTELLI A, RUBINI C, FIORONI M, LEZZI G, SANTINELLI A. Prevalence of p53, bcl-2, and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in premalignant and malignant lesions of the oral cavity. J Oral Maxillofac Surg 2002: 60: 532-540.
97. PIFFKO J, BANKFALVI A, OFNER D, BRYNE M, RASCH D, JOOS, U, BOCKER W, SCHMID KW. Prognostic value of histobiological factors (malignancy grading and AgNOR content) assessed at the invasive tumour front of oral squamous cell carcinomas. Br J Cancer 1997: 75: 1643-1546.
98. RALHAN R, NATH N, AGARWAL S, MATHUR M, WASYLYK B, SHUKLA NK. Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations. Clin Cancer Res 1998: 4: 2147-2152.
99. RALHAN R, SWAIN RK, AGARWAL S, KAUR J, NATH N, SARKAR G, MATHUR M, SHUKLA NK. P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 1999: 84: 80-85.
100. RALHAN R, AGARWAL S, MATHUR M, WASYLYK B, SRIVASTAVA A. Association between polymorphism in p21(Waf1/ Cip1) cyclin-dependent kinase inhibitor gene and oral cancer. Clin Cancer Res 2000: 6: 2440-2447.
101. RAVI D, NALINAKUMARI KR, RAJARAM RS, NAIR MK, PILLAI MR. Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Lett 1996: 105: 139-146.
102. RAVI D, RAMADAS K, MATHEW BS, NALIAKUMARI KR, NAIR MK, PILLAI MR. De novo programmed cell death in oral cancer. Histopathology 1999: 34: 241-249.
103. RAVI D, RAMADAS K, MATHEW BS, NALINAKUMARI KR, NAIR MK, PILLAI MR. Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol 1998: 34: 543-548.
104. RAVI D, RAMADAS K, MATHEW BS, PANIKKAR KR, NAIR MK, PILLAI MR. Apoptosis, angiogenesis and proliferation: trifunctional measure of tumour response to radiotherapy for oral cancer. Oral Oncol 2001: 37: 164-171.
105. RAVINDRANATH NM, NISHIMOTO K, CHU K, SHULER C. Cell-surface expression of complement restriction factors and sialyl lewis antigens in oral carcinoma: relevance to immunochemotherapy. Anticancer Res 2000: 20: 21-26.
106. REICHERT TE, DAY R, WAGNER EM, WHITESIDE TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998: 58: 5344-5347.
107. REICHERT TE, SCHEUER C, DAY R, WAGNER W, WHITESIDE TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001: 91: 2136-2147.
108. RHEINWALD JG, HAHN WC, RAMSEY MR, WU JY, GUO Z, TSAO H, DE LUCA M, CATRICALA C, O'TOOLE KM. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002: 22: 5157-5172.
109. ROUSSEAU A, LIM MS, LIN Z, JORDAN RC. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 2001: 37: 268-275.
110. SAKAKI T, WATO M, TAMURA I, NAKAJIMA M, MORITA S, KAKUDO K, SHIRASU R, TANAKA A. Correlation of E-cadherin and alpha-catenin expression with differentiation of oral squamous cell carcinoma. J Osaka Dent Univ 1999: 33: 75-81.
111. SAKURAI K, URADE M, TAKAHASHI Y, KISHIMOTO H, NOGUCHI K, YASOSHIMA H, KUBOTA A. Increased expression of c-erbB-3 protein and proliferating cell nuclear antigen during development of verruccous carcinoma of the oral mucosa. Cancer 2000: 89: 2597-2605.
112. SANO T, HIKINO T, XUE Q, SAITO T, KASHIWABARA K, OYAMA T, NAKAJIMA T. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma. Pathol Int 2000: 50: 709-716.
113. SARTOR M, STEINGRIMSDOTTIR H, ELAMIN F, GAKEN J, WARNAKULASURIJYA S, PARTRIDGE M, THAKKER N, JOHNSON NW, TAVASSOLI M. Role of p16/MTS1, Cyclin D1 and RB in primary oral cancer and oral cell. Br J Cancer 1999: 80: 79-86.
114. SCHOELCH ML, REGEZI JA, CEKKER NP, NG IO, MCMILLAN A, ZIOBER BL, LE QT, SILVERMAN S, FU KK. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999: 35: 333-342.
115. SCHOELCH ML, LE QT, SILVERMAN S JR, MCMILLAN A, DEKKER NP, FU KK, ZIOBER BL, REGEZI JA. Apoptosis-related proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999: 35: 77-85.
116. SCHWARTZ JL, GU X, KITTIES RA, BAPTISTE A, SHKLAR G. Experimental oral carcinoma of the tongue and buccal mucosa: possible biologic markers linked to cancers at two anatomic sites. Oral Oncol 2000: 36: 225-235.
117. SCULLY C, FIELD JK, TANZAWA H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncology 2000: 36: 256-263.
118. SCULLY C, FIELD JK, TANZAWA H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2; chromosomal aberrations. Oral Oncology 2000: 36: 311-327.
119. SETA C, FUJITA M, MURAKI Y, FUKUDA J, KOBAYASHI S, HANEJ T. Fas expression and Fas monoclonal antibody-induced apoptosis in a human squamous cell carcinoma cell line, SCC-25. J Oral Pathol Med 2000: 29: 271-278.
120. SHAHNAVAZ SA, REGEZI JA, BRADLEY G, DUBE ID, JORDAN RC. P53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. J Pathol 2000: 190: 417-422.
121. SHEN H, ZHENG Y, STURGIS EM, SPITZ MR, WEI Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002: 183: 123-130.
122. SHIMAMOTO H. Telomerase activity ion oral squamous cell carcinoma and leukoplakia. Kokubyo Gakkai Zasshi 2001: 68: 125-133.
123. SHINADA T, NAKAMURA H, YAMASHITA K, KAWATA R, MURAKAMI Y, FUJIMOTO N, SATO H, SEIKI M, OKADA Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matric metalloproteinase in human cell carcinomas: implication s for lymph node metastasis. Clin Exp Metastasis 2000: 18: 179-188.
124. SHINDOH M, ADACHI M, HIGASHINO F, YASUDA M, HIDA K, NISHIOKA T, ONO M, TAKAYAMA S, REED JC, IMAI K, TOTSUKA Y, KOHGO T. BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol 2000: 36: 444-449.
125. SHINTANI S, KIYOTA A, MIHARA M, NAKAHARA Y, TERAKADO N, UEYAMA Y, MATSUMURA T. Association of preoperative radiation effect with tumour angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res 2000: 91: 1051-1057.
126. SHINTANI S, MIHARA M, UEYAMA Y, MATSUMARA T, WONG DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001: 96: 159-165.
127. SHINTANI S, MIHARA M, TERAKADO N, NAKAHARA Y, MATSUMURA T, KOHNO Y, OHYAMA H, MCBRIDE J, KENT R, TODD R, TSUJI T, WONG DT. Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res 2001: 7: 2776-2782.
128. SHINTANI S, MIHARA M, NAKAHARA Y, KIYOTA A, UEYAMA Y, MATSUMURA T, WONG DT. Expression of cell cycle control proteins in normal epithelium, pre-malignant and malignant lesions of oral cavity. Oral Oncol 2002: 38: 235-243.
129. SHINOHARA M, NAKAMURA S, SASAKI M, KURAHARA S, IKEBE T, HARADA T, SHIRASUNA K. Expression of integrins in squamous cell carcinoma of the oral cavity. Correlations with tumor invasion and metastasis. Am J Clin Pathol 1999: 111: 75-88.
130. SINOHARA M, HIRAKI A, IKEBE T, NAKAMURA S, KURAHARA S, SHIRASUNA K, GARROD DR. Immunohistochemical study of desmosomes in oral squamous cell carcinoma: correlation with cytokeratin and E-cadherin staining and with tumour behaviour.
131. SITTEL C, RUIZ S, VOLLING P, KVASNICKA HM, JUNGEHULSING M, ECKEL HE. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999: 35: 583-589.
132. SMITH BD, SMITH GL, CARTER D, SASAKI CT, HAFFTY BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000: 18: 2040-2052.
133. SMITH BD, SMITH GL, CARTER D, DIGIOVANNA MP, KASOWITZ KM, SASAKI CT, HAFFTY BG. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001: 127: 780-785.
134. STOLL C, BARETTON G, AHRENS C, LOHRS U. Prognostic significance of apoptosis in oral squamous cell carcinoma. Virchows Arch 2000: 436: 102-108.
135. SUMIDA T, HAMAKAWA H, SOGAWA K, SUGITA A, TANIOKA H, UEDA N. Telomerase components as a diagnostic tool in human oral lesions. Int J Cancer 1999: 80: 1-4.
136. SUTINEN M, KAINULAINEN T, HURSKAINEN T, VESTERLUND E, ALEXANDER JP, OVERALL CM, SORSA T, SALO T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998: 77: 2239-2245.
137. TAE K, EI-NAGGAR AK, YOO E, FENG L, LE JJ, HONG WK, HITTELMAN WN, SHIN DM. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 2000: 6: 2821-2828.
138. TAKES RP, BAATENBURG DE JONG RJ, ALLES MJ, MEEUWIS CA, MARRES HA, KNEGT PP, DE LA RIVIERE GB, DE WILDE PC, MOOI WJ, HERMANS J, VAN KRIEKEN JH. Markers for nodal metastasis in head and neck squamous cell cancer. Arch Otolaryngol Head Neck Surg 2002: 128: 512-518.
139. TAMURA N, DONG Y, SUI L, TAI SUGIMOTO K, NAGAHATA S, TOKUDA M. Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas. J Laryngol Otol 2001: 115: 400-406.
140. THOMAS GJ, JONES J, SPEIGHT PM. Integrins and oral cancer. Oral Oncol 1997: 33: 381-388.
141. THOMAS GJ, JONES J, SPEIGHT PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999: 35: 227-233.
142. THOMAS GJ, SPEIGHT PM. Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med 2001: 12: 479-498.
143. THOMAS GJ, LEWIS MP, HART IR, MARSHALL JF, SPEIGHT PM. AlphaV-beta6 integrin promotes invasion of squamous cell carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001: 92: 641-650.
144. TRALONGO V, RODOLICO V, LUVIANI A, MARRA G, DANIELE E. Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res 1999: 19: 3503-3510.
145. UNAL OF, AYHAN A, HOSAL AS. Prognostic value of p53 expression and histopathological parameters in squamous cell carcinoma of the tongue. J Laryngol Otol 1999: 113: 446-450.
146. UNO M, OTSUKI T, YATA K, FUJII T, SAKAGUCHI H, AKISADA T, HIRATSUKA J, IMAJO Y, HARADA T. Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation. Int J Oncol 2002: 20: 617-622.
147. VAIDYA MM, SAWANT SS, BORGES AM, OGALE SB, BHISEY AN. Cytokeratin expression in precancerous lesions of the human oral cavity. Oral Oncol 1998: 34: 261-264.
148. VAN DER TOORN PP, VELTMAN JA, BOT FJ, DE JONG JM, MANNI JJ, RAMAEKERS FC, HOPMAN AH. Mapping of resection margins of oral cancer for p53 overexpression and chromosome instability to detect residual (pre)malignant cells. J Pathol 2001: 191: 66-72.
149. VAN HEERDEN WF, VAN RENSBURG EJ, HEMMER J, RAUBENHEIMER EJ, ENGELBRECHT S. Correlation of p53 gene mutation, p53 labelling and PCNA expression in oral squamous cell carcinomas. Anticancer Res 1998: 18: 237-240.
150. VENTURA L, MIGALDI M, CRISCUOLO M, CASTELLI M, BARBOLINI G, RANIERI A, BIFARETTI G, UBOLDI P, LEOCATA P. Nucleolar protein p120 expression in oral carcinoma. Anticancer Res 1999: 19: 1423-1426.
151. VIGNESWARAN N, ZHAO W, DASSANAYAKE A, MULLER S, MILLER DM, ZACHARIAS W. Variable expression of Cathepsin B and D correlates with highly invasive and metastatic phenotype of cancer. Hum Pathol 2000: 31: 931-937.
152. WARNAKULASURIYA S. Lack of molecular markers to predict malignant potential of oral cancer. J Pathol 2000: 190: 407-409.
153. WARNAKULASURIYA KA, TAVASSOLI M, JOHNSON NW. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 1998: 27: 376-381.
154. WEI N, TAHAN SR. S100+ cell response to squamous cell carcinoma of the lip: inverse correlation with metastasis. J Cutan Pathol 1998: 25: 463-468.
155. WERKMEISTER R, BRANDT B, JOOS U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 2000: 36: 100-105.
156. WERKMEISTER R, BRANDT B, JOOS U. Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity. Br J Oral Maxillofac Surg 1999: 6: 477-480.
157. 2 terminal kinase-2. Cancer Res 2000: 60: 7156-7162.
158. WILKMAN TS, HIETANEN JH, MALSTROM MJ, KONTIINEN YT. Immunohistochemical analysis of the oncoprotein c-erbN-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg 1998: 27: 209-212.
159. XIA W, LAU YK, ZHANG HZ, LIU AR, LI L, KIYOKAWA N, CLAYMAN GL, KATZ RL, HUNG MC. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997: 3: 3-9.
160. XIA W, LAU YK, ZHANG HZ, XIAO FY, JOHNSTON DA, LIU AR, LI L, KATZ RL, HUNG MC. Combination of EFGR, Her-2/neu and Her-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999: 5: 4164-4174.
161. XIE X, DE ANGELIS P, CLAUSEN OP, BOYSEN M. Prognostic significance of proliferative and apoptotic markers in oral tongue. Oral Oncol 1999: 35: 502-509.
162. XIE X, CLAUSEN OP, DE ANGELIS P, BOYSEN M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999: 86: 913-920.
163. XIE X, CLAUSEN OP, SUDBO J, BOYSEN M. Diagnostic and prognostic value of nucleolar organizer regions in normal epithelium, dyplasia and squamous cell carcinoma of the oral cavity. Cancer 1999: 79: 2200-2208.
164. YAMAMOTO T, YONEDA K, UEDA E, DOI S, OSAKI T. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation. Eur J Cancer 2000: 36: 2007-2017.
165. YOKOTA T, IKEDA H, INOKUCHI T, SANO K, KOJI T. Enhanced cell death in NR-S1 tumor by photodynamic therapy: possible involvement of Fas and Fas ligand system. Lasers Surg Med 2000: 26: 449-460.
166. YOOK JI, Kim J. Expression of p21waf1/ cip1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol 1998: 34: 198-203.
167. YUE L, LAWI M, FUERTA I. Evaluation of agyrophilic nucleolar organizer regions in tongue squamous cell carcinomas. Oral Oncol 1999: 35: 70-76.
168. YUEN PW, MAN M, LAM KY, KWONG YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002: 55: 58-60.
169. ZIOBER BL, SILVERMAN SS JR, KRAMER RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 2001: 12: 499-510.